About the Program

SymBiosis and HealthTech Arkansas are partnering to build and execute an accelerator program for biotherapeutics companies ready to conduct a clinical trial within 12 months of entry or for companies moving to next phase of clinical trial

2022 - 2023 Program Dates
Applications Open
  • Oct
    19
    2022
  • Feb
    28
    2023
Cohort Chosen
  • Apr
    1
    2023
Program Kickoff
  • May
    1
    2023
Program Overview

The BioAR Trial accelerator is designed for:

  • Companies in late-stage preclinical studies and planning to enter clinical trials in the next 12 months, or companies entering phase II or III studies.
  • Seeking an expedited clinical trial with renowned principal investigators and diverse patient populations
Our Focus

Advanced and emerging therapeutic modalities applied to serious and life-threatening diseases

  • Modalities may include precision medicines, biologics, cell therapies, or genetic medicines
  • Disease areas may include oncology, immunology, metabolic and cardiovascular
How it works:
1

Companies will be recruited worldwide to apply to the program

2

A selection committee comprised of representatives from our partner health systems and clinical trials sites will review and interview the ten finalist companies to select the five companies to be admitted to the program

3

Each of the five companies admitted to the program will be guaranteed a clinical trial site in Arkansas

4

The BioAR Trial team will work with each of the five companies to facilitate their clinical trial

Program Benefits

A guaranteed clinical site in Arkansas at one of the leading academic medical centers or healthcare provider organizations

The company will be paired with a principal investigator in their therapeutic area who access to a relevant patient population

An experienced clinical trials manager at HealthTech Arkansas to help facilitate and expedite the trial whenever possible, leveraging that individual’s knowledge of the participating clinical trial sites

Collaboration with HealthTech Arkansas to build an economic value model for your asset

Establish a relationship with SymBiosis, a venture capital firm investing in biotherapeutics

The companies will be invited to attend a biotechnology conference in Northwest Arkansas, which will be an opportunity for the company to network with industry executives

Support of the Northwest Arkansas region (capital, foundations, healthcare ecosystem, government, etc.)

Meet the Team
Amber Neil
HealthTech Arkansas
Jeff Stinson
HealthTech Arkansas
Priya Bargoti
HealthTech Arkansas
About Our Organizations

SymBiosis Capital Management, LLC is an investment firm focused on advancing biotherapeutics innovations. Led by Chidozie Ugwumba, Managing Partner, along with an experienced team of professionals, SymBiosis invests across disease area, financing stage, and geography, with a focus on programs in, or about to enter, human trials. The firm currently manages a portfolio of more than 30 investments and has significant, long-term capital commitments to fund future investments. For more information, please visit www.symbiosis.vc or follow us on LinkedIn.

HealthTech Arkansas is an organization that helps drive innovation for the ten largest hospitals and health systems in Arkansas, which they accomplish through accelerator programs and internal innovation programming. The firm’s flagship program, HeartX, is an annual accelerator currently focused on cardiovascular technologies. The program guarantees at least two hospital pilot projects or clinical trials for each early-stage company admitted to the program.

In addition to the guaranteed pilots, participating companies receive upfront investment from the HealthTech Arkansas Fund. The company’s internal innovation programming is focused on helping the state’s healthcare provider organizations to harvest, organize and develop ideas for new innovations from their own clinicians and administrators. The organization does this through a variety of specific programs focused on solving real problems and challenges (clinical and administrative in nature) through the development and commercialization of intellectual property to be owned by the provider organization.